Does Russia need a treat-to-target initiative?

Rheumatology (Oxford). 2015 Mar;54(3):381-2. doi: 10.1093/rheumatology/keu156. Epub 2014 Apr 15.

Authors

Eugeny L Nasonov¹, Dmitry E Karateev²

Affiliations

¹ Department of Vascular Pathology of Rheumatic Diseases and Early Arthritis Department, Research Institute of Rheumatology, Russian Academy of Medical Sciences (RAMS), Moscow, Russian Federation.
² Department of Vascular Pathology of Rheumatic Diseases and Early Arthritis Department, Research Institute of Rheumatology, Russian Academy of Medical Sciences (RAMS), Moscow, Russian Federation. karateev@irramn.ru dekar@inbox.ru.

PMID: 24736164
DOI: 10.1093/rheumatology/keu156

No abstract available

Publication types

Editorial

MeSH terms

Antihypertensive Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / epidemiology
Biological Products / therapeutic use*
Humans
Molecular Targeted Therapy / trends*
Practice Patterns, Physicians' / trends
Prevalence
Program Development*
Russia / epidemiology

Substances

Antihypertensive Agents
Biological Products